nivolumab,axitinib,ipilimumab,pembrolizumab
pfizer,merck,bms
['nivo', 'pembro', 'rcc,(-irccs),(-srcc),(-urcc)', 'nivolumab', 'ipilimumab', 'axitinib']
healthcare resource utilization and costs for patients with #mrcc receiving first-line pembrolizumab + axitinib or ipilimumab + nivolumab. presented by neil shah, mbbs . #asco22 written coverage by &gt; 
Largest global online community of #urological medical professionals & patients. #AUA22 #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology